News
The FDA is allowing Sarepta to resume shipments of Elevidys (delandistrogene moxeparvovec) to ambulatory patients with Duchenne muscular dystrophy.
1d
GlobalData on MSNHansa’s Idefirix shows potential as pre-treatment to ElevidysHansa Biosciences’ Idefirix (imlifidase) has reduced patients’ antibodies to a level that allows dosing in patients with ...
5h
The New Republic on MSNLaura Loomer Is Getting a Taste of Her Own MedicineAs Laura Loomer wields a terrifying amount of power, other far-right influencers are accusing her of being a “plant.” ...
7hOpinion
The New Republic on MSNTrump’s DOJ Reveals It Has Recording of Ghislaine MaxwellIn his first town hall since voting in favor of Donald Trump’s “big, beautiful bill,” Nebraska Representative Mike Flood had ...
I do not work for Big Pharma. I work in support of President Trump on the outside of the administration,’ Loomer tells The ...
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...
8hOpinion
The New Republic on MSNTexas Republican Accidentally Admits Truth About GOP’s GerrymanderingTexas state Representative Mitch Little confessed the simple reality of his party’s sudden push for a new congressional map.
Parents of boys with Duchenne muscular dystrophy weigh in on drug innovation and medical regulation.
I understand the heartbreak of watching someone you love spiral. But compassion cannot mean locking people up,” writes a STAT ...
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results